I'm actually a bit confused here. We are going in the opposite direction for one thing. For another, we still have no clarity on what the impact is with how the testing is effecting the deals with China and Malaysia.
I know they have to put in the IND, but this can take 3 weeks or so. I believe the Malaysia deal relies on the FDA response, but does the China deal?
Because of the issues with the CC, there were really not a lot of questions that were asked and answered, so Generex really should put out something as a follow-up to help shareholders understand what the heck is going on.
We heard very positive results from the test, but what does it mean for overseas deals. We know what it means for the US - waiting. But we have 2.5 billion dollars worth of deals overseas along with a NGIO listing to boot.
So, follow-ups would be helpful.
I know they have to put in the IND, but this can take 3 weeks or so. I believe the Malaysia deal relies on the FDA response, but does the China deal?
Because of the issues with the CC, there were really not a lot of questions that were asked and answered, so Generex really should put out something as a follow-up to help shareholders understand what the heck is going on.
We heard very positive results from the test, but what does it mean for overseas deals. We know what it means for the US - waiting. But we have 2.5 billion dollars worth of deals overseas along with a NGIO listing to boot.
So, follow-ups would be helpful.
3
